This contract opportunity involves the establishment of non-exclusive discount agreements for the pharmaceutical product Denosumab, marketed as Xgeva, in accordance with German social law. The contracts will be valid from July 1, 2025, to June 30, 2027, and suppliers can enter into agreements at any
280 days left to bid. Opened 1 years ago, deadline 30 Apr 2027.
The AOK Rheinland-Pfalz/Saarland - The Health Fund is issuing a framework agreement for "Seating Furniture" consisting of a total of 4 lots. This specific tender is for Lot 3, which involves establishing a framework agreement for the purchase, delivery to the designated location, assembly/installati
The Open-House procedure for pharmaceutical discount contracts involving the active ingredient Pazopanib (ATC L01EX03), identified by the code "484904-2024", will be terminated effective January 31, 2026. Existing contracts will be canceled at that time, and no new contracts can be concluded under t
This contract opportunity involves the establishment of non-exclusive discount contracts for the pharmaceutical products Naproxen and Esomeprazole, in accordance with German social law. The contracts will be valid from February 1, 2026, to January 31, 2028, and suppliers can enter into contracts at
This contract opportunity involves the establishment of non-exclusive discount contracts for the medication Glatiramer Acetate, specifically for pre-filled syringes. The contracts will be in effect from February 1, 2026, to January 31, 2028, with the option for suppliers to enter into contracts at a
NHS Scotland is seeking suppliers of generic and biosimilar cancer medicines to improve patient access and optimize healthcare costs.
Royal Borough of Greenwich is commissioning a School Health and Wellbeing Service to deliver preventative health and early intervention support for children and young people aged 5-19 years across the borough, with contract commencement in April 2027.
Suffolk County Council is testing market interest for postal delivery of nicotine replacement therapy and smoking cessation medications to improve accessibility for local residents.
PSD Scotland is engaging with the market to explore delivery solutions for a national Targeted Lung Cancer Screening Programme for smokers aged 55-74 in Scotland.
